businesspress24.com - GENEWIZ Expands Next Generation Sequencing Services With Cancer Panels
 

GENEWIZ Expands Next Generation Sequencing Services With Cancer Panels

ID: 1176336

(firmenpresse) - SOUTH PLAINFIELD, NJ -- (Marketwire) -- 12/03/12 -- , leading global genomic service provider, announced today expansion of their Next Generation Sequencing service portfolio to include . Available through and platforms, Cancer Panels enable GENEWIZ to screen for genetic mutations proven to play a role in cancer.

Advanced next generation sequencing technologies enable cancer panels to target over fifty cancer genes with deep sequencing, providing a high depth of coverage sensitive enough to detect rare mutations from a very small amount of DNA.

"NGS-based cancer panels allow for rapid analysis of multiple genes at a considerably lower price compared to traditional sequencing techniques," stated Dr. Yankai Jia, Director of GENEWIZ Next Generation Sequencing. "The large amount of data generated is highly technical, so it's important for researchers to have a trusted partner throughout the process who can provide the customized support and scientific expertise required."

In addition to offering the and Cancer Panels, GENEWIZ is actively developing custom cancer panels in effort to further advance cancer research, biomarker discovery, clinical diagnostics, and personalized medicine.

For more information about GENEWIZ Next Generation Sequencing Cancer Panels, please .

is a global contract research organization (CRO) specializing in genomic services, including DNA sequencing, gene synthesis, molecular biology, genomic, bioinformatics, and GxP/CLIA regulatory-compliant services. GENEWIZ leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic, and government institutions.

Headquartered in South Plainfield, NJ, GENEWIZ, Inc. is a privately-held global enterprise with locations in Boston, MA; San Diego, CA; Washington, DC Metro; Research Triangle Park, NC; and Seattle, WA. International locations include Beijing, China; Suzhou, China; and London, United Kingdom.










Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Improving Trend in FDA First Cycle Review Approvals a Major Factor for Biotech Industry's Success in 2012
Horizon Pharma Begins Initial Commercial Launch of RAYOS(R) (prednisone) Delayed-Release Tablets in the United States
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 03.12.2012 - 04:00 Uhr
Sprache: Deutsch
News-ID 1176336
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

SOUTH PLAINFIELD, NJ


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 162 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"GENEWIZ Expands Next Generation Sequencing Services With Cancer Panels
"
steht unter der journalistisch-redaktionellen Verantwortung von

GENEWIZ, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von GENEWIZ, Inc.



 

Who is online

All members: 10 566
Register today: 1
Register yesterday: 0
Members online: 0
Guests online: 100


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.